Across the globe, pharma companies are encountering new levels of price resistance and competitive pressure.  Providing compelling evidence to demonstrate differentiated value has been recognized as key to mitigating these pressures.  However, restrictive regulations threaten to significantly change the financial picture across the industry, such that no functional area will be immune to budget cuts.  As budgets for evidence generation become tighter, organizations will need to approach evidence planning and generation in a manner that ensures the greatest value for the resource spend.

Read More

Thank you for your interest in our content. Registering allows you to access a wide range of informative articles, briefs, and whitepapers throughout the site.

Privacy is important. We do not share registrant information with anyone outside of Numerof & Associates. For details, please see our Privacy Policy. Subscribers to our mailings can unsubscribe instantly at any time.